Steun ons werk
Decorative header background

Internet-guided cognitive, behavioral and chronobiological interventions in depression-prone insomnia subtypes

Onderzoeksgroep Van Someren
Publicatiejaar 2020
Gepubliceerd in BMC Psychiatry
Auteur(s) Jeanne Leerssen, Jessica C Foster-Dingley, Oti Lakbila-Kamal, Laura M S Dekkers, Anne C W Albers, Savannah L C Ikelaar, Teodora Maksimovic, Rick Wassing, Simon J Houtman, Tom Bresser, T.F. Blanken, Bart H W Te Lindert, Jennifer R Ramautar, Eus Van Someren

BACKGROUND: Major depressive disorder is among the most burdening and costly chronic health hazards. Since its prognosis is poor and treatment effectiveness is moderate at best, prevention would be the strategy of first choice. Insomnia may be the best modifiable risk factor. Insomnia is highly prevalent (4-10%) and meta-analysis estimates ±13% of people with insomnia to develop depression within a year. Among people with insomnia, recent work identified three subtypes with a particularly high lifetime risk of depression. The current randomized controlled trial (RCT) evaluates the effects of internet-guided Cognitive Behavioral Therapy for Insomnia (CBT-I), Chronobiological Therapy (CT), and their combination on insomnia and the development of depressive symptoms.

METHODS: We aim to include 120 participants with Insomnia Disorder (ID) of one of the three subtypes that are more prone to develop depression. In a two by two factorial repeated measures design, participants will be randomized to CBT-I, CT, CBT-I + CT or treatment as usual, and followed up for one year. The primary outcome is the change, relative to baseline, of the severity of depressive symptoms integrated over four follow-ups spanning one year. Secondary outcome measures include a diagnosis of major depressive disorder, insomnia severity, sleep diaries, actigraphy, cost-effectiveness, and brain structure and function.

DISCUSSION: Pre-selection of three high-risk insomnia subtypes allows for a sensitive assessment of the possibility to prevent the development and worsening of depressive symptoms through interventions targeting insomnia.

TRIAL REGISTRATION: Netherlands Trial Register (NL7359). Registered on 19 October 2018.

Steun ons werk

De Stichting Vrienden van het Herseninstituut ondersteunt baanbrekend hersenonderzoek. U kunt ons daarbij helpen.

Steun ons werk